All studies
AuthorisedTherapeutic confirmatory (Phase III)Interventional

Standard-dose versus high-dose prophylactic anticoagulation in critically ill medical patients at risk for thromboprophylaxis failure: a multicentre, parallel-group, double-blind, phase III, randomized controlled trial

When people are treated in an intensive care unit (ICU), being resting in bed makes them prone to blood clots in their legs or lungs. Doctors usually give blood-thinning injections, such as enoxaparin, to help prevent these clots. However, the standard dose does not always protect everyone, especially those at higher risk. This trial compares the usual standard dose of enoxaparin against a higher dose in critically ill patients. Researchers want to see if a higher dose gives better protection against clots without increasing the risk of serious bleeding. Patients are randomly chosen to receive either the standard or the higher dose while in hospital. Doctors monitor them closely for 28 days, with a final follow-up at six months. The aim is to find the safest, most effective dose to protect critically ill patients.

At a glance

Status
Authorised
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Hopital Erasme
Enrolment target
666
Start
19 Oct 2026

What is this study about?

Patients admitted to an intensive care unit (ICU) are often very ill and cannot move around easily. When you are still for long periods, your blood flows more slowly, which raises the chance of a blood clot forming in your deep veins (known as deep vein thrombosis, or DVT). If a piece of this clot breaks away and travels to the lungs, it can cause a serious condition called a pulmonary embolism. Doctors routinely give preventative blood-thinning medicines to reduce this danger.

Even with standard preventative treatment, some critically ill patients still develop blood clots. Doctors wonder if giving a higher dose of enoxaparin, a well-known blood thinner, might protect high-risk patients better. However, giving more blood-thinning medication can also raise the chance of bleeding, so it is vital to test whether the benefits outweigh the risks.

This trial is designed to provide clear answers. It compares the standard dose directly with a higher dose to see which approach helps patients more. By finding the right balance between stopping clots and avoiding bleeding, this study hopes to improve recovery and survival rates for future intensive care patients across the UK and beyond.

Key takeaways

  • Tests whether a higher dose of the blood thinner enoxaparin works better than the standard dose in intensive care.
  • Aims to reduce dangerous blood clots in the legs and lungs while checking for bleeding risks.
  • Open to critically ill adults aged 18 and older who are treated in an intensive care unit.
  • Participants receive daily injections while in hospital, with follow-ups at 28 days and 6 months.
  • Joining is voluntary, and taking part will not disrupt any other necessary hospital treatments.

Who may be eligible?

This study is for adults aged 18 or older who are admitted to an intensive care unit for a medical illness and are considered at high risk of developing a blood clot despite standard prevention.

Men and women of any age over 18 can take part. Because intensive care patients are often very unwell, people do not need to walk or be fully awake to be considered.

People might not be able to join if they already have an active, serious bleed, an allergy to blood-thinning medicines, or another condition that makes taking extra blood thinners unsafe. The medical team will check every patient's safety before they are entered into the trial.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. You are aged 18 or older.
  2. You are currently receiving treatment in an intensive care unit (ICU).
  3. You have a medical illness that puts you at higher risk for blood clots.
  4. You do not have any active, dangerous internal bleeding.
  5. You do not have a known allergy to enoxaparin or similar blood thinners.
Answer every question to see your result.

What does participation involve?

Because participants are already in the intensive care unit, taking part does not require any extra hospital visits. Patients receive their study medicine as a daily injection under the skin, which is the normal way enoxaparin is given.

A computer randomly decides whether the patient gets the standard dose or the higher dose. Neither the patient nor the bedside doctors will know which dose is being given, ensuring the results are completely fair. Normal care continues as usual, and staff will check daily for any signs of clots or bleeding.

Doctors will track the patient's progress closely for the first 28 days. A member of the research team will also check in at six months (Day 180) to see how the patient is recovering and whether they have been able to return home.

Potential risks and benefits

The possible benefit of taking part is better protection against life-threatening blood clots in the legs or lungs. However, higher doses of blood thinners can increase the risk of bleeding or bruising. The medical team watches participants very closely to catch and treat any issues straight away. Taking part is completely voluntary. Patients or their families can choose to leave the study at any time, and this will never affect the quality of medical care they receive.

Locations (2)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    France
  • —
    Unverified
    Belgium

Common questions

What is enoxaparin?

Enoxaparin is a common, trusted blood-thinning medication given by an injection just under the skin. It helps stop harmful blood clots from forming inside blood vessels.

Why do patients in intensive care get blood clots?

Being confined to bed means blood does not circulate as quickly. In addition, severe illness causes inflammation in the body, which makes blood more likely to clot.

How is the dose decided?

A computer system assigns patients by chance to receive either the standard dose or the higher dose. This ensures the study gives completely unbiased results.

What if the patient is too unwell to give consent?

If a patient is unconscious or too sick to decide, doctors will speak with their family or a legal representative to seek their agreement before enrolling them.

Will this change my usual intensive care treatment?

No. All regular treatments, scans, and nursing care will continue as normal. Only the dose of the preventative blood thinner is adjusted for the study.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.